Andere Sprachen Ceapro Inc.

Aktien

931278

CA1499071076

CZO

Markt geschlossen - Toronto S.E. Andere Börsenplätze 15:30:00 30.04.2024			% 5 Tage	% 1. Jan.
0.24 ^CAD	-7.69%		-.--%	+26.32%

27.03.	Aeterna Zentaris meldet für das 4. Quartal einen Nettoverlust von 5,6 Millionen US-Dollar und gibt ein Update zur DETECT-Studie	MT
2023	Aeterna Zentaris und Ceapro kündigen Fusion von Gleichberechtigten an, um ein diversifiziertes biopharmazeutisches Unternehmen zu schaffen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29.04.
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29.04.
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28.03.
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28.03.
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	28.03.
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27.03.
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27.03.
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27.03.
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12.03.
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12.03.
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	26.02.
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26.02.
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	26.02.
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	23.02.
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	15.02.
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	15.02.
Canadian Investment Regulatory Organization Trade Resumption - CZO	14.12.
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14.12.
Canadian Investment Regulatory Organization Trading Halt - CZO	14.12.
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	14.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ceapro Inc.

Aktien

931278

CA1499071076

CZO

Andere Sprachen

Filter